Rachit Khandelwal/X
Apr 23, 2025, 08:35
Rachit Khandelwal: India’s First POC CAR-T Trial shows 100% CR in B-ALL
Rachit Khandelwal, Pediatrics BMT fellow at Medanta The Medicity, shared an article by Hamenth Kumar Palani, et al. on X:
“India’s First POC CAR-T Trial: VELCART.
Point-of-care anti-CD19 CAR-T therapy shows 100% CR in B-ALL, low cost and no serious toxicity.
A breakthrough for LMICs—accessible, affordable, effective. Published in Molecular Therapy Oncology.”
Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial.
Authors: Hamenth Kumar Palani, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 08:35
Apr 23, 2025, 08:18
Apr 23, 2025, 08:09
Apr 23, 2025, 07:49
Apr 23, 2025, 07:21
Apr 23, 2025, 06:49